The application for the Pfizer-BioNTech vaccine to be used in children aged six months to four years old has been delayed, the Food and Drug Administration announced Friday.

The company submitted the emergency use authorization application on February 1. It included data from the first two doses of the three-dose vaccine set to be used in younger children. A FDA advisory committee panel meeting to discuss the merits of the approval was scheduled for February 15

Data for a third shot was supposed to come in later, and the New York City based company planned to apply for authorization for the third shot at another time.

The FDA said Friday it was notified by Pfizer that the company had new data regarding the shot that was worthy of being included in the decision making process.  

As a result, the February 15 meeting has been pushed back to an unknown date. 

Despite the push from regulators to expand eligibility for the shots to include young children, the controversial move would make the U.S. the only nation to jab children under one years old for Covid.

Despite the push from regulators to expand eligibility for the shots to include young children, the controversial move would make the U.S. the only nation to jab children under one years old for Covid. 

Source: | This article originally belongs to Dailymail.co.uk

You May Also Like

Minister says polio ‘outbreak’ source could be narrowed down to ONE home or street

The source of the polio virus found in sewage samples could be…

Security guards at South Australia’s medi-hotels sacked or stood down for protocol breaches

Almost 100 private security guards at South Australia’s medi-hotels have been fired…

New insights into the formation of toxic protein clumps in Alzheimer’s disease

Small Aβ oligomers (left: cryo-electron microscopy) are clumps consisting of just a…

Black women are up to four times more likely to die of COVID-19 compared to white men

[ad_1] Two new studies have revealed the impact the coronavirus pandemic had…